Aims
Aims Assess therapeutic profile of Assess therapeutic profile of cannabis and cannabinoids. cannabis and cannabinoids.
Method Method Medline search, references
Medline search, references supplied by DOH and others, and supplied by DOH and others, and personal communications. personal communications.
Results and Conclusions Results and Conclusions Cannabis
Cannabis and some cannabinoids are effective anti-and some cannabinoids are effective antiemetics and analgesics and reduce intra-emetics and analgesics and reduce intraocular pressure.There is evidence of ocular pressure.There is evidence of symptomrelief andimproved well-beingin symptomrelief andimproved well-beingin selected neurological conditions, AIDS and selected neurological conditions, AIDS and certain cancers.Cannabinoids may reduce certain cancers.Cannabinoids may reduce anxiety and improve sleep. Anticonvulsant anxiety and improve sleep. Anticonvulsant activity requires clarification.Other activity requires clarification.Other properties identified by basic research properties identified by basic research await evaluation. Standard treatments for await evaluation. Standard treatments for many relevant disorders are many relevant disorders are unsatisfactory.Cannabis is safe in overdose unsatisfactory.Cannabis is safe in overdose but often produces unwanted effects, but often produces unwanted effects, typically sedation, intoxication, typically sedation, intoxication, clumsiness, dizziness, dry mouth, lowered clumsiness, dizziness, dry mouth, lowered blood pressure or increased heart rate. blood pressure or increased heart rate. The discovery of specific receptors and The discovery of specific receptors and naturalligands may lead to drug naturalligands may lead to drug developments.Research is needed to developments.Research is needed to optimise dose and route of administration, optimise dose and route of administration, quantify therapeutic and adverse effects, quantify therapeutic and adverse effects, and examine interactions. and examine interactions.
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In 1996 I was commissioned by the Depart-In 1996 I was commissioned by the Department of Health (DOH) to review the ment of Health (DOH) to review the scientific literature regarding the potential scientific literature regarding the potential therapeutic utility of cannabis and its therapeutic utility of cannabis and its derivatives. The review was based upon derivatives. The review was based upon primary sources (identified from a Medline primary sources (identified from a Medline literature search, reference lists supplied by literature search, reference lists supplied by the DOH and the Institute for the Study of the DOH and the Institute for the Study of Drug Dependence, and personal communi-Drug Dependence, and personal communications with relevant academics and cations with relevant academics and clinicians). This paper is a greatly shortened clinicians). This paper is a greatly shortened version of the review. The 4 years which version of the review. The 4 years which have elapsed have seen little in the way of have elapsed have seen little in the way of new clinical results but considerable new clinical results but considerable advances in cannabinoid basic science advances in cannabinoid basic science (Institute of Medicine, 1999) . Government (Institute of Medicine, 1999) . Government licences have recently been granted for licences have recently been granted for several controlled trials of both synthetic several controlled trials of both synthetic and plant-derived cannabinoids in multiple and plant-derived cannabinoids in multiple sclerosis and chronic pain. In January 2000, sclerosis and chronic pain. In January 2000, I was appointed Medical Director of GW I was appointed Medical Director of GW Pharmaceuticals, a company established to Pharmaceuticals, a company established to derive medicinal extracts from standardised derive medicinal extracts from standardised cannabis plants. cannabis plants.
HISTORY OF THER APEUTIC HISTORY OF THER APEUTIC USE USE
The first formal report of cannabis as a The first formal report of cannabis as a medicine appeared in China nearly 5000 medicine appeared in China nearly 5000 years ago when it was recommended for years ago when it was recommended for malaria, constipation, rheumatic pains and malaria, constipation, rheumatic pains and childbirth and, mixed with wine, as a childbirth and, mixed with wine, as a surgical analgesic (Mechoulam, 1986) . surgical analgesic (Mechoulam, 1986) . There are subsequent records of its use There are subsequent records of its use throughout Asia, the Middle East, Southern throughout Asia, the Middle East, Southern Africa and South America. Accounts by Africa and South America. Accounts by Pliny, Dioscorides and Galen remained Pliny, Dioscorides and Galen remained influential in European medicine for 16 influential in European medicine for 16 centuries. centuries.
It was not until the 19th century that It was not until the 19th century that cannabis became a mainstream medicine cannabis became a mainstream medicine in Britain. W. B. O'Shaughnessy, an Irish in Britain. W. B. O'Shaughnessy, an Irish scientist and physician, observed its use in scientist and physician, observed its use in India as an analgesic, anticonvulsant, anti-India as an analgesic, anticonvulsant, antispasmodic, anti-emetic and hypnotic. After spasmodic, anti-emetic and hypnotic. After toxicity experiments on goats and dogs, he toxicity experiments on goats and dogs, he gave it to patients and was impressed with gave it to patients and was impressed with its muscle-relaxant, anticonvulsant and its muscle-relaxant, anticonvulsant and analgesic properties, and recorded its use-analgesic properties, and recorded its usefulness as an anti-emetic. fulness as an anti-emetic.
After these observations were published After these observations were published in 1842, medicinal use of cannabis ex-in 1842, medicinal use of cannabis expanded rapidly. It soon became available panded rapidly. It soon became availablè over the counter' in pharmacies and bỳover the counter' in pharmacies and by 1854 it had found its way into the United 1854 it had found its way into the United States Dispensatory. The American market States Dispensatory. The American market became flooded with dozens of cannabis-became flooded with dozens of cannabiscontaining home remedies. containing home remedies.
Queen Victoria's personal physician Queen Victoria's personal physician wrote (Reynolds, 1890) , on the basis of wrote (Reynolds, 1890) , on the basis of more than 30 years' experience, that more than 30 years' experience, that`I ndian hemp, when pure and administered`Indian hemp, when pure and administered carefully, is one of the most valuable carefully, is one of the most valuable medicines we possess''. He found it incom-medicines we possess''. He found it incomparable for``senile insomnia'',``night parable for``senile insomnia'',``night restlessness'' and``temper disease'' in both restlessness'' and``temper disease'' in both children and adults, but not helpful in children and adults, but not helpful in melancholia,``very uncertain'' in alcoholic melancholia,``very uncertain'' in alcoholic delirium, and``worse than useless'' in delirium, and``worse than useless'' in mania. It was very effective in neuralgia, mania. It was very effective in neuralgia, period pains, migraine,``lightning pain of period pains, migraine,``lightning pain of the ataxic patient'' and gout, but useless the ataxic patient'' and gout, but useless in sciatica and``hysteric pains''. He in sciatica and``hysteric pains''. He found it impressive in clonic spasms and found it impressive in clonic spasms and certain epileptiform convulsions related certain epileptiform convulsions related to brain damage, but no good at all in to brain damage, but no good at all in petit mal or``chronic epilepsy'', tetanus, petit mal or``chronic epilepsy'', tetanus, chorea or paralysis agitans. It effectively chorea or paralysis agitans. It effectively relieved nocturnal cramps, asthma and relieved nocturnal cramps, asthma and dysmenorrhoea. dysmenorrhoea.
Reynolds was writing at a time when Reynolds was writing at a time when the zenith of cannabis as prescribed medicine the zenith of cannabis as prescribed medicine and home remedy was already past. and home remedy was already past. Although Sir William Osler was still recom-Although Sir William Osler was still recommending it for migraine sufferers in 1913, it mending it for migraine sufferers in 1913, it was by then in steep decline because of was by then in steep decline because of variable potency of herbal preparations, variable potency of herbal preparations, poor storage stability, unpredictable poor storage stability, unpredictable response to oral administration, increasing response to oral administration, increasing enthusiasm for parenteral medicines and enthusiasm for parenteral medicines and availability of potent synthetic alternatives, availability of potent synthetic alternatives, commercial pressures and American con-commercial pressures and American concern about recreational use. Cannabis was cern about recreational use. 
CANNABINOID CANNABINOID PHARMACOLOGY RELEVANT PHARMACOLOGY RELEVANT TO THER APEUTICS TO THER APEUTICS
Cannabinol was isolated in 1895 and canna-Cannabinol was isolated in 1895 and cannabidiol in 1934, but the most significant dis-bidiol in 1934, but the most significant discovery was that of covery was that of D D 9 9 -tetrahydrocannabinol -tetrahydrocannabinol (THC) in 1964. Chromatographic and (THC) in 1964. Chromatographic and spectroscopic methods subsequently spectroscopic methods subsequently un-uncovered many closely related compounds. covered many closely related compounds.
Capsules of synthetic THC (dronabinol) Capsules of synthetic THC (dronabinol) have been available for restricted medical have been available for restricted medical use in the USA since 1985. Nabilone, a use in the USA since 1985. Nabilone, a synthetic THC analogue, was marketed in synthetic THC analogue, was marketed in 1983 and is the only cannabinoid licensed 1983 and is the only cannabinoid licensed for prescription in the UK, restricted to for prescription in the UK, restricted to treatment of nausea and vomiting caused treatment of nausea and vomiting caused by cytotoxic chemotherapy unresponsive by cytotoxic chemotherapy unresponsive to conventional anti-emetics. Use in other to conventional anti-emetics. Use in other indications is only possible on a`named indications is only possible on a`named patient' basis if the drug is supplied by a patient' basis if the drug is supplied by a hospital pharmacy. hospital pharmacy.
In 1988, a specific protein receptor In 1988, a specific protein receptor (known as CB (known as CB 1 1 ) for THC was discovered ) for THC was discovered in mouse nerve cells. This mediates most in mouse nerve cells. This mediates most of the central nervous system (CNS) of the central nervous system (CNS) responses to cannabinoids, and is abundant responses to cannabinoids, and is abundant in basal ganglia, hippocampus and cere-in basal ganglia, hippocampus and cerebellum, globus pallidus, substantia nigra bellum, globus pallidus, substantia nigra and cerebral cortex. An endogenous ligand and cerebral cortex. An endogenous ligand was identified in 1992 and labelled ananda-was identified in 1992 and labelled anandamide ( mide (ananda ananda:`bliss' in Sanskrit). Ananda-:`bliss' in Sanskrit). Anandamide has analgesic and tranquillising mide has analgesic and tranquillising effects in animals, is involved in muscle effects in animals, is involved in muscle coordination and affects the secretion and coordination and affects the secretion and function of certain hormones. Other endo-function of certain hormones. Other endogenous agonists almost certainly exist. genous agonists almost certainly exist.
In 1993, a second receptor (CB In 1993, a second receptor (CB 2 2 ) was ) was identified in rat spleen macrophages, and identified in rat spleen macrophages, and this occurs only outside the CNS. There is this occurs only outside the CNS. There is scope for chemical manipulation of canna-scope for chemical manipulation of cannabinoids to maximise selectivity for CB binoids to maximise selectivity for CB 2 2 and so avoid psychoactive effects. It is and so avoid psychoactive effects. It is thought this receptor has relevance for thought this receptor has relevance for anti-inflammatory and immunosuppressive anti-inflammatory and immunosuppressive activity. activity.
Pertwee (1995) has suggested that the Pertwee (1995) has suggested that the anandamide system might be concerned anandamide system might be concerned with mood, memory and cognition, percep-with mood, memory and cognition, perception, movement, coordination, posture and tion, movement, coordination, posture and skeletal muscle tone, sleep, thermo-skeletal muscle tone, sleep, thermoregulation, appetite and immune response. regulation, appetite and immune response.
CLINICAL APPLICATIONS CLINICAL APPLICATIONS

Nausea and vomiting Nausea and vomiting
Many cytotoxic drugs are powerful Many cytotoxic drugs are powerful emetics, and this is the major limiting factor emetics, and this is the major limiting factor in patients' acceptance of cancer chemo-in patients' acceptance of cancer chemotherapy (see Table 1 and Appendix). therapy (see Table 1 and Appendix).
Many recreational smokers receiving Many recreational smokers receiving cancer chemotherapy have told their cancer chemotherapy have told their doctors that cannabis relieved their nausea doctors that cannabis relieved their nausea (Grinspoon & Bakalar, 1993) . Sallan (Grinspoon & Bakalar, 1993) . Sallan et al et al's 's (1975) randomised control trial (RCT) com-(1975) randomised control trial (RCT) compared oral THC and placebo in 22 cancer pared oral THC and placebo in 22 cancer patients who had proved resistant to con-patients who had proved resistant to conventional anti-emetics. Comparisons using ventional anti-emetics. Comparisons using patients' self-reports of nausea and patients' self-reports of nausea and vomiting demonstrated that THC was vomiting demonstrated that THC was statistically superior to placebo. THC statistically superior to placebo. THC (10 mg/m (10 mg/m 2 2 ) produced euphoria in the major-) produced euphoria in the majority ity of patients, and one-third experienced of patients, and one-third experienced sedation. sedation.
Subsequent RCTs (listed in Table 1 ) Subsequent RCTs (listed in Table 1 ) confirmed that natural and synthetic THC confirmed that natural and synthetic THC is invariably superior to placebo. Compari-is invariably superior to placebo. Comparisons with anti-emetics available in the sons with anti-emetics available in the 1970s and 1980s suggest that THC is either 1970s and 1980s suggest that THC is either equivalent in effect or better. A com-equivalent in effect or better. A combination of prochlorperazine and THC bination of prochlorperazine and THC was superior to either drug alone, and nabi-was superior to either drug alone, and nabilone combined with prochlorperazine was lone combined with prochlorperazine was better than dexamethazone plus meto-better than dexamethazone plus metoclopramide. Although THC and nabilone clopramide. Although THC and nabilone produced more unwanted effects than com-produced more unwanted effects than comparison drugs, patients generally preferred parison drugs, patients generally preferred them. them.
Children seem to respond well to Children seem to respond well to nabilone and are tolerant of side-effects, nabilone and are tolerant of side-effects, but larger studies are required. but larger studies are required. D D 8 8 -THC -THC performed well in a pilot study performed well in a pilot study (Abrahamov (Abrahamov et al et al, 1995 ) involving eight , 1995 involving eight children aged 3±13 years with various children aged 3±13 years with various blood cancers receiving chemotherapy, blood cancers receiving chemotherapy, 60% of whom had experienced distressing 60% of whom had experienced distressing vomiting despite treatment with metoclo-vomiting despite treatment with metoclopramide. pramide. D D 8 8 -THC was given orally 2 hours -THC was given orally 2 hours before cytotoxics and repeated 6-hourly. before cytotoxics and repeated 6-hourly. No vomiting was recorded during this No vomiting was recorded during this treatment and over the following 2 days. treatment and over the following 2 days. Two children were``slightly irritable'' and Two children were``slightly irritable'' and one also showed``slight euphoria''. one also showed``slight euphoria''.
In a review of 12 studies involving 600 In a review of 12 studies involving 600 patients (Penta patients (Penta et al et al, 1981) , THC was , 1981), THC was`e ffective'' in 8/9 and nabilone in 3/3.`effective'' in 8/9 and nabilone in 3/3. The most common side-effects were somno-The most common side-effects were somnolence (33%), dry mouth (9%), ataxia (8%), lence (33%), dry mouth (9%), ataxia (8%), dizziness (6%), dysphoria (6%), and ortho-dizziness (6%), dysphoria (6%), and orthostatic hypotension (4%). A further review static hypotension (4%). A further review (Levitt, 1986) incorporating 55 studies, of (Levitt, 1986) incorporating 55 studies, of which 32 were RCTs, showed that low-dose which 32 were RCTs, showed that low-dose preventive treatment gives better results than preventive treatment gives better results than targeting established vomiting. Younger targeting established vomiting. Younger patients may respond better than older ones. patients may respond better than older ones.
Meta-analysis (Plasse Meta-analysis (Plasse et al et al, 1991) , 1991) suggested that an optimal balance of effi-suggested that an optimal balance of efficacy and unwanted effects was achieved cacy and unwanted effects was achieved with relatively modest doses (7 mg/m with relatively modest doses (7 mg/m 2 2 or or less). Sedation and psychotropic symptoms less). Sedation and psychotropic symptoms are commonly reported, but are usually are commonly reported, but are usually mild to moderate in intensity and resolve mild to moderate in intensity and resolve rapidly on discontinuation. No``persistent rapidly on discontinuation. No``persistent or fatal'' adverse effects have been or fatal'' adverse effects have been reported. Many American oncologists reported. Many American oncologists encourage nauseous patients to try canna-encourage nauseous patients to try cannabis and would prescribe it if it were legal bis and would prescribe it if it were legal (Doblin & Kleiman, 1991) . Mode of action (Doblin & Kleiman, 1991) . Mode of action remains uncertain. remains uncertain.
Multiple sclerosis and other Multiple sclerosis and other neurological conditions neurological conditions
Drug therapy of muscle spasticity is gener-Drug therapy of muscle spasticity is generally only moderately effective and is limited ally only moderately effective and is limited by adverse effects (see Appendix). Spasticity by adverse effects (see Appendix). Spasticity is a central feature of multiple sclerosis is a central feature of multiple sclerosis (MS), cerebral palsy and spinal cord injury. (MS), cerebral palsy and spinal cord injury. Tremor, ataxia and incontinence also Tremor, ataxia and incontinence also con-contribute to the high incidence of anxiety and tribute to the high incidence of anxiety and depression in these conditions. Cannabis depression in these conditions. Cannabis was often used to treat pain, muscle spasm, was often used to treat pain, muscle spasm, cramps and ataxia in the 19th century, and cramps and ataxia in the 19th century, and many modern sufferers have reported many modern sufferers have reported benefits (Grinspoon & Bakalar, 1993) . benefits (Grinspoon & Bakalar, 1993) .
Most respondents to a questionnaire Most respondents to a questionnaire sent to British and American MS patients re-sent to British and American MS patients reported problems with symptom control ported problems with symptom control (Consroe (Consroe et al et al, 1997) . Those who smoked , 1997). Those who smoked cannabis claimed improvements in night-cannabis claimed improvements in nighttime spasticity and muscle pain (91±98%); time spasticity and muscle pain (91±98%); night leg pain, depression, tremor, anxiety, night leg pain, depression, tremor, anxiety, spasms on walking, paraesthesiae (80± spasms on walking, paraesthesiae (80± 89%); leg weakness, trunk numbness, facial 89%); leg weakness, trunk numbness, facial pain (71±74%); impaired balance (57%); pain (71±74%); impaired balance (57%); constipation (33%); memory loss (31%). constipation (33%); memory loss (31%).
In a small single-blind comparison with In a small single-blind comparison with placebo (Clifford, 1983) , THC improved placebo (Clifford, 1983) , THC improved tremor and ataxia in most patients. All ex-tremor and ataxia in most patients. All experienced a`high' at the top dose (15 mg), perienced a`high' at the top dose (15 mg), and two reported dysphoria. Dose-related and two reported dysphoria. Dose-related improvements in improvements in dystonia were noted in dystonia were noted in five patients given cannabidiol 100± five patients given cannabidiol 100± 600 mg daily for 600 mg daily for 6 weeks. Hypotension, 6 weeks. Hypotension, dry mouth, sedation and light-headedness dry mouth, sedation and light-headedness occurred but were described as mild. occurred but were described as mild. Parkinsonian symptoms were aggravated Parkinsonian symptoms were aggravated in two subjects. in two subjects.
An RCT by Petro & Ellenberger (1981) An RCT by Petro & Ellenberger (1981) compared the effects of placebo and THC compared the effects of placebo and THC in doses of 5 or 10 mg on muscle tone, in doses of 5 or 10 mg on muscle tone, reflexes and muscle power in nine MS reflexes and muscle power in nine MS patients. Both doses of THC reduced patients. Both doses of THC reduced spasticity ( spasticity (P P5 50.005). One patient receiving 0.005). One patient receiving THC 10 mg and one patient receiving THC 10 mg and one patient receiving placebo felt`high' but no other side-effects placebo felt`high' but no other side-effects were recorded. In a small RCT (Ungerleider were recorded. In a small RCT (Ungerleider et al et al, 1987) with 5-day treatment periods, , 1987) with 5-day treatment periods, THC 7.5 mg significantly improved spasti-THC 7.5 mg significantly improved spasticity in comparison with placebo. Nabilone city in comparison with placebo. Nabilone 1 mg on alternate days was compared with 1 mg on alternate days was compared with placebo in a double-blind randomised cross-placebo in a double-blind randomised crossover over trial with 4-week treatment periods in trial with 4-week treatment periods in a single MS patient. Nocturia, muscle spasm a single MS patient. Nocturia, muscle spasm and general well-being showed striking and general well-being showed striking improvement during each active treatment improvement during each active treatment period. Mild sedation was noted on active period. Mild sedation was noted on active medication. medication.
Cannabidiol had no beneficial effects in Cannabidiol had no beneficial effects in 15 patients with Huntington's disease (Con-15 patients with Huntington's disease (Consroe sroe et al et al, 1991) . Posture and balance were , 1991). Posture and balance were impaired by a single dose of smoked THC impaired by a single dose of smoked THC in 10 MS patients and 10 non-MS volun-in 10 MS patients and 10 non-MS volunteers (Greenberg teers (Greenberg et al et al, 1994) , but there , 1994), but there was no active control to determine the was no active control to determine the effects of standard anti-spastic medication effects of standard anti-spastic medication in this model. in this model.
Possible sites of action of cannabinoids in Possible sites of action of cannabinoids in dystonia include basal ganglia, cerebellum, dystonia include basal ganglia, cerebellum, spinal motor neurons, somatic nerves and spinal motor neurons, somatic nerves and neuromuscular junction. neuromuscular junction.
Loss of appetite and weight Loss of appetite and weight in cancer and AIDS in cancer and AIDS
Several studies have investigated effect on Several studies have investigated effect on appetite and weight ( Table 2 ). The appetite-appetite and weight ( Table 2 ). The appetitestimulating effect of cannabis was confirm-stimulating effect of cannabis was confirmed in fasting and non-fasting volunteers in ed in fasting and non-fasting volunteers in an RCT of oral THC with alcohol, an RCT of oral THC with alcohol, amphetamine and placebo (Hollister, 1971) . amphetamine and placebo (Hollister, 1971) . A standardised THC smoking regime over A standardised THC smoking regime over 25 days in a residential laboratory was 25 days in a residential laboratory was 1 0 9 1 0 9 Nabilone was significantly superior in reducing nausea and vo-Nabilone was significantly superior in reducing nausea and vomiting frequency, but produced more lethargy and miting frequency, but produced more lethargy and hypotension. Nabilone was preferred by 75% of patients hypotension. Nabilone was preferred by 75% of patients THC was significantly superior to prochlorperazine ( THC was significantly superior to prochlorperazine (P P5 50.005). 0.005).
Side-effects were evenly distributed, except that THC Side-effects were evenly distributed, except that THC produced a`high' in 82% of patients produced a`high' in 82% of patients associated with significant increases in calorie associated with significant increases in calorie intake and frequency of eating occasions in intake and frequency of eating occasions in comparison with placebo. comparison with placebo. Open studies in cancer patients also Open studies in cancer patients also showed appetite improvements and slowing showed appetite improvements and slowing of weight loss. Regelson of weight loss. Regelson et al et al's (1976) RCT 's (1976) RCT explored the effect on appetite (and mood) explored the effect on appetite (and mood) of oral THC in 54 cancer patients over a of oral THC in 54 cancer patients over a 2-week period. There were nine with-2-week period. There were nine withdrawals drawals due to side-effects (six in THC due to side-effects (six in THC period ± dizziness, disassociation, confused period ± dizziness, disassociation, confused thinking, panic,``feelings of disturbance''; thinking, panic,``feelings of disturbance''; three in the placebo period ± anxiety, fits, three in the placebo period ± anxiety, fits, dizziness, lethargy, weakness). Patients dizziness, lethargy, weakness). Patients receiving THC in the first period gained receiving THC in the first period gained weight ( weight (P P5 50.05), and those receiving 0.05), and those receiving placebo first showed reduced weight loss placebo first showed reduced weight loss on transfer to THC ( on transfer to THC (P P5 50.05). Depression, 0.05). Depression, tranquillity and``forthrightness'' scores all tranquillity and``forthrightness'' scores all improved on THC. In a quarter of the improved on THC. In a quarter of the patients, somnolence, dizziness and dis-patients, somnolence, dizziness and disassociation were severe enough to negate association were severe enough to negate these effects. these effects.
Many people with AIDS have claimed Many people with AIDS have claimed that smoking marijuana inhibits nausea, that smoking marijuana inhibits nausea, improves appetite, reduces anxiety, relieves improves appetite, reduces anxiety, relieves aches and pains, improves sleep and in-aches and pains, improves sleep and inhibits oral candidiasis. A small pilot study hibits oral candidiasis. A small pilot study supported the hypothesis that dronabinol supported the hypothesis that dronabinol might reduce weight loss or even promote might reduce weight loss or even promote weight gain (Plasse weight gain (Plasse et al et al, 1991) . , 1991).
Beal
Beal et al et al (1995) conducted an RCT over (1995) conducted an RCT over 42 days of treatment with dronabinol 5 mg 42 days of treatment with dronabinol 5 mg daily in 139 AIDS patients who had lost at daily in 139 AIDS patients who had lost at least 2.3 kg. Six receiving dronabinol and least 2.3 kg. Six receiving dronabinol and three receiving placebo withdrew because three receiving placebo withdrew because of``perceived drug toxicity''. Dronabinol of``perceived drug toxicity''. Dronabinol boosted appetite in comparison to placebo boosted appetite in comparison to placebo ( (P P5 50.015) and nausea was reduced 0.015) and nausea was reduced ( (P P0.05). Improvement in mood was a 0.05). Improvement in mood was a strong trend ( strong trend (P P0.06) and there was a 0.06) and there was a tendency toward weight gain ( tendency toward weight gain (P P0.1). 0.1). Dronabinol produced more adverse effects Dronabinol produced more adverse effects than placebo ( than placebo (P P5 50.001), but 75% of these 0.001), but 75% of these were mild or moderate. Most frequent were were mild or moderate. Most frequent were euphoria (9), dizziness (5), thinking euphoria (9), dizziness (5), thinking abnorm-abnormalities (5) and sedation (4). alities (5) and sedation (4).
Further investigation is amply justified. Further investigation is amply justified. Careful monitoring of possible effects upon Careful monitoring of possible effects upon the immune system is needed, although a the immune system is needed, although a prospective multi-centre study (Kaslow prospective multi-centre study (Kaslow et et al al, 1989) , which followed nearly 5000 , 1989), which followed nearly 5000 HIV-positive men for 18 months, showed HIV-positive men for 18 months, showed no link between use of psychoactive sub-no link between use of psychoactive substances and mean T-cell counts or progres-stances and mean T-cell counts or progression to AIDS. sion to AIDS.
Pain Pain
Cannabinoids are effective analgesics in Cannabinoids are effective analgesics in animal models with non-opiate mechan-animal models with non-opiate mechanisms predominating. There are many isms predominating. There are many anecdotal reports (Grinspoon & Bakalar, anecdotal reports (Grinspoon & Bakalar, 1993) of benefits in bone and joint pain, 1993) of benefits in bone and joint pain, migraine, cancer pain, menstrual cramps migraine, cancer pain, menstrual cramps and labour. and labour.
Five small RCTs (Table 3) show that Five small RCTs (Table 3) show that THC is significantly superior to placebo THC is significantly superior to placebo and produces dose-related analgesia peak-and produces dose-related analgesia peaking at around 5 hours, comparable to but ing at around 5 hours, comparable to but out-lasting that of codeine. Side-effects out-lasting that of codeine. Side-effects were also dose-related, and consisted of were also dose-related, and consisted of slurred speech, sedation and mental cloud-slurred speech, sedation and mental clouding, blurred vision, dizziness and ataxia. ing, blurred vision, dizziness and ataxia. Levonantradol was also superior to placebo Levonantradol was also superior to placebo and notably long-acting, but almost half the and notably long-acting, but almost half the patients reported sedation. Cannabinoids patients reported sedation. Cannabinoids may have considerable potential in neuro-may have considerable potential in neuropathic pain (Institute of Medicine, 1999) . pathic pain (Institute of Medicine, 1999).
Raised intra-ocular pressure Raised intra-ocular pressure Glaucoma due to obstructed outflow of Glaucoma due to obstructed outflow of aqueous humour or anatomical eye defects aqueous humour or anatomical eye defects is the most common cause of blindness in is the most common cause of blindness in the Western world. Some RCTs investi-the Western world. Some RCTs investigating this area are given in Table 4 . gating this area are given in Table 4 .
There have been many anecdotal There have been many anecdotal reports that street marijuana can relieve reports that street marijuana can relieve glaucoma symptoms and individuals have glaucoma symptoms and individuals have successfully argued in the USA for legal successfully argued in the USA for legal access to the drug (Grinspoon & Bakalar, access to the drug (Grinspoon & Bakalar, 1993) . A pilot study of smoked marijuana 1993). A pilot study of smoked marijuana 11 0 11 0 and oral THC (15 mg) in 11 glaucoma and oral THC (15 mg) in 11 glaucoma patients found an average intra-ocular pres-patients found an average intra-ocular pressure (IOP) reduction of 30% in seven sub-sure (IOP) reduction of 30% in seven subjects and no response in four (Hepler jects and no response in four (Hepler et et al al, 1976 (Hepler et et al al, ). , 1976 . Randomised controlled trials in volun-Randomised controlled trials in volunteers confirmed that oral, injected or teers confirmed that oral, injected or smoked cannabinoids produce dose-related smoked cannabinoids produce dose-related reductions of IOP (Hepler reductions of IOP (Hepler et al et al, 1976; Perez-Reyes Perez-Reyes et al et al, 1976) . Conjunctival , 1976) . Conjunctival engorgement and tear reduction were engorgement and tear reduction were often often noted. THC, noted. THC, D D 8 8 -THC and 11-hydroxy--THC and 11-hydroxy-THC THC are more effective than cannabinol, while are more effective than cannabinol, while cannabidiol was without effect. Tolerance cannabidiol was without effect. Tolerance may develop on multiple dosing. may develop on multiple dosing.
An RCT in patients showed IOP An RCT in patients showed IOP reductions of similar magnitude following reductions of similar magnitude following smoked THC along with``alterations in smoked THC along with``alterations in mental status'' and tachycardia (Merritt mental status'' and tachycardia (Merritt et et al al, 1980) . THC eyedrops produced dose-, 1980) . THC eyedrops produced doserelated IOP reduction with minimal side-related IOP reduction with minimal sideeffects though parallel reductions in the effects though parallel reductions in the untreated eye (also seen in animal models) untreated eye (also seen in animal models) suggested a systemic rather than local suggested a systemic rather than local mode of action. mode of action.
Insomnia, anxiety and depression Insomnia, anxiety and depression
Randomised controlled trials investigating Randomised controlled trials investigating insomnia, anxiety and depression are given insomnia, anxiety and depression are given in Table 5 . in Table 5 .
Nabilone (1 mg three times daily) pro-Nabilone (1 mg three times daily) produced``dramatic improvements'' on the duced``dramatic improvements'' on the Hamilton Anxiety Scale in 20 anxious Hamilton Anxiety Scale in 20 anxious patients in comparison to placebo patients in comparison to placebo ( (P P5 50.001), which were mirrored by other 0.001), which were mirrored by other measures (Fabre & McLendon, 1981) . measures (Fabre & McLendon, 1981) . Seven days into the study, nabilone Seven days into the study, nabilone patients' anxiety scores were halved, and patients' anxiety scores were halved, and this persisted unchanged throughout treat-this persisted unchanged throughout treatment. Side-effects included dry mouth, dry ment. Side-effects included dry mouth, dry eyes and drowsiness. The authors con-eyes and drowsiness. The authors concluded that nabilone is a``very effective cluded that nabilone is a``very effective anxiolytic deserving of further study''. In anxiolytic deserving of further study''. In a cross-over comparison of nabilone (1± a cross-over comparison of nabilone (1± 2.5 mg twice daily) and placebo in 11 2.5 mg twice daily) and placebo in 11 anxious patients (Ilaria anxious patients (Ilaria et al et al, 1981) , signifi-, 1981), significant improvements in anxiety scores cant improvements in anxiety scores ( (P P5 50.05) were again noted. The only clini-0.05) were again noted. The only clinically significant adverse effect was postural cally significant adverse effect was postural hypotension with related dizziness, light-hypotension with related dizziness, lightheadedness or weakness. This was dose-headedness or weakness. This was doserelated, experienced by most patients, and related, experienced by most patients, and tended to tolerate out over time. tended to tolerate out over time.
Preliminary data suggest that canna-Preliminary data suggest that cannabidiol (160 mg) may be an effective bidiol (160 mg) may be an effective hypnotic, and that THC (0.1 mg/kg) may hypnotic, and that THC (0.1 mg/kg) may have antidepressant properties in cancer have antidepressant properties in cancer patients and others (Grinspoon & Bakalar, patients and others (Grinspoon & Bakalar, 1993) . 1993).
Epilepsy Epilepsy
Epilepsy afflicts 1% of the world's popu-Epilepsy afflicts 1% of the world's population. Conventional anticonvulsants pro-lation. Conventional anticonvulsants provide unsatisfactory control for up to 30% vide unsatisfactory control for up to 30% of patients, and all can produce disabling of patients, and all can produce disabling or even life-threatening adverse effects. or even life-threatening adverse effects.
The effect of cannabinoids on seizure The effect of cannabinoids on seizure activity in laboratory animals is compli-activity in laboratory animals is complicated. Cannabidiol is a powerful anti-cated. Cannabidiol is a powerful anticonvulsant free of tolerance, but its profile convulsant free of tolerance, but its profile varies between species. THC can produce varies between species. THC can produce seizures in big doses or when genetically seizures in big doses or when genetically seizure-sensitive animals are used, yet it is seizure-sensitive animals are used, yet it is also robustly anticonvulsant in certain also robustly anticonvulsant in certain seizure models. A lack of stereospecificity seizure models. A lack of stereospecificity suggests that the mechanism may not be suggests that the mechanism may not be related to a single receptor interaction. related to a single receptor interaction. Serotonin, Serotonin, g g-aminobutyric acid, acetylcho--aminobutyric acid, acetylcholine or prostaglandin systems may be line or prostaglandin systems may be involved. involved.
There are many anecdotal reports of There are many anecdotal reports of beneficial effects in humans with epilepsy beneficial effects in humans with epilepsy (Grinspoon & Bakalar, 1993) but research (Grinspoon & Bakalar, 1993) with secondary generalised epilepsy con-with secondary generalised epilepsy continued with their regular therapy but were tinued with their regular therapy but were also given either cannabidiol or placebo also given either cannabidiol or placebo daily for up to 4.5 months while under-daily for up to 4.5 months while undergoing regular clinical and electro-going regular clinical and electroencephalogram evaluation. Half the encephalogram evaluation. Half the patients on cannabidiol remained``almost patients on cannabidiol remained``almost free'' of fits throughout the experiment, free'' of fits throughout the experiment, and all but one of the others showed``par-and all but one of the others showed``partial improvement''. All but one of the tial improvement''. All but one of the placebo patients remained entirely un-placebo patients remained entirely unchanged. Somnolence occurred in four changed. Somnolence occurred in four patients receiving cannabidiol. patients receiving cannabidiol.
Asthma Asthma
Small-scale controlled studies in volunteers Small-scale controlled studies in volunteers with asthma show that oral, smoked and with asthma show that oral, smoked and aerosolised THC has comparable broncho-aerosolised THC has comparable bronchodilatory activity to salbutamol, although dilatory activity to salbutamol, although onset is quicker with the latter. Dose-onset is quicker with the latter. Dose-related related tachycardia occurred in some individuals, tachycardia occurred in some individuals, and subjective intoxication with higher and subjective intoxication with higher doses. A THC aerosol was free of systemic doses. A THC aerosol was free of systemic unwanted effects, but was irritant to the unwanted effects, but was irritant to the lungs (Tashkin lungs (Tashkin et al et al, 1977) . Nabilone does , 1977) . Nabilone does not produce bronchodilation. Since THC-not produce bronchodilation. Since THCinduced bronchodilation is not mediated induced bronchodilation is not mediated through the sympathetic nervous system, through the sympathetic nervous system, synergistic combinations with synergistic combinations with b b 2 2 -adreno--adrenoceptor stimulants might be possible. ceptor stimulants might be possible.
Other possible therapeutic Other possible therapeutic applications applications
Basic research indicates that THC and Basic research indicates that THC and analogues inhibit opioid withdrawal analogues inhibit opioid withdrawal (Chesher & Jackson, 1985) . Anecdotal (Chesher & Jackson, 1985) . Anecdotal reports from patients also point to benefi-reports from patients also point to beneficial effects beyond those which could be cial effects beyond those which could be accounted for by sedative or hypnotic accounted for by sedative or hypnotic activity. Cannabinoids inhibit primary activity. Cannabinoids inhibit primary tumour growth and increase survival in tumour growth and increase survival in animal tumour models (Harris animal tumour models (Harris et al et al, 1976) , 1976) by an unknown mechanism. They also by an unknown mechanism. They also show antipyretic and anti-inflammatory show antipyretic and anti-inflammatory activity (Formukong activity (Formukong et al et al, 1989) . , 1989). Mechoulam (1986) has drawn attention to Mechoulam (1986) has drawn attention to the lack of modern research directed at the lack of modern research directed at possible antihelmintic, antimigraine and possible antihelmintic, antimigraine and oxytocic applications. oxytocic applications.
DISCUSSION DISCUSSION
Therapeutic profile on existing Therapeutic profile on existing evidence evidence Tetrahydrocannabinol and nabilone are Tetrahydrocannabinol and nabilone are effective anti-effective anti-emetics but there are no com-emetics but there are no comparisons with 5-HT parisons with 5-HT 3 3 antagonists, so a role antagonists, so a role in modern anti-emetic regimes remains to in modern anti-emetic regimes remains to be determined. Currently, only nabilone is be determined. Currently, only nabilone is licensed in the UK and available for pre-licensed in the UK and available for prescription and research. THC (as dron-scription and research. THC (as dronabinol) has recently been rescheduled to abinol) has recently been rescheduled to permit prescription but remains unlicensed permit prescription but remains unlicensed and must be specially imported on a and must be specially imported on a named-patient basis. Delta-8-THC looks named-patient basis. Delta-8-THC looks worthy of further investigation, particularly worthy of further investigation, particularly in children, and is much simpler to synthe-in children, and is much simpler to synthesise than THC. sise than THC. Many individuals with MS have claimed Many individuals with MS have claimed a benefit from cannabis and small controlled a benefit from cannabis and small controlled trials support this, although effect upon pos-trials support this, although effect upon posture and balance requires clarification. THC ture and balance requires clarification. THC is an effective analgesic at the expense of is an effective analgesic at the expense of sedation with larger doses and may have sedation with larger doses and may have special merit in neuropathic pain. No conclu-special merit in neuropathic pain. No conclusions are possible as yet about anticonvulsant sions are possible as yet about anticonvulsant potential. Some potential. Some cannabinoids reduce IOP, cannabinoids reduce IOP, though side-though side-effects of products currently effects of products currently available limit application and effects of tol-available limit application and effects of tolerance are uncertain. The mechanism for erance are uncertain. The mechanism for bronchodilation bronchodilation probably differs from that probably differs from that of of b b 2 2 --stimulants, so synergistic combinations stimulants, so synergistic combinations may be possible. may be possible.
Cannabis and THC are effective Cannabis and THC are effective appetite stimulants. Alongside anti-emetic, appetite stimulants. Alongside anti-emetic, analgesic, anxiolytic, hypnotic and anti-analgesic, anxiolytic, hypnotic and antipyretic properties this suggests a unique pyretic properties this suggests a unique role in alleviating symptoms in selected role in alleviating symptoms in selected patients with cancer or AIDS. This is a patients with cancer or AIDS. This is a compelling area for future research, compelling area for future research, although possible effects upon immune although possible effects upon immune function require careful monitoring. function require careful monitoring.
Optimal doses and routes of delivery Optimal doses and routes of delivery have not been established. Absorption by have not been established. Absorption by the oral route is unreliable. Smoking the the oral route is unreliable. Smoking the drug is generally not a viable option since drug is generally not a viable option since advantages such as rapid onset, accurate advantages such as rapid onset, accurate titration of effects and reliability in patients titration of effects and reliability in patients who are vomiting have to be set against the who are vomiting have to be set against the likelihood of lung irritation or damage, and likelihood of lung irritation or damage, and it would in any case be unacceptable to it would in any case be unacceptable to most patients. However, pending avail-most patients. However, pending availability of more satisfactory preparations, I ability of more satisfactory preparations, I believe that the existing profile of efficacy believe that the existing profile of efficacy and toxicity justifies the provision of a and toxicity justifies the provision of a legal supply of standardised herbal material legal supply of standardised herbal material (`compassionate reefers') to patients with (`compassionate reefers') to patients with terminal conditions who currently obtain terminal conditions who currently obtain relief with street cannabis. Sublingual relief with street cannabis. Sublingual sprays or tablets, nebulisers and aerosols sprays or tablets, nebulisers and aerosols look promising for the future, and THC is look promising for the future, and THC is effective by the rectal route. effective by the rectal route. Many poten-Many potentially active cannabinoids tially active cannabinoids have yet to be have yet to be investigated and the recent identification investigated and the recent identification of a peripheral receptor may lead to of a peripheral receptor may lead to new drugs devoid of central nervous new drugs devoid of central nervous system effects. system effects.
Cannabis arouses passion in those who
Cannabis arouses passion in those who support or condemn it, and few people support or condemn it, and few people approach the clinical literature with dis-approach the clinical literature with dispassionate objectivity. Poorly controlled passionate objectivity. Poorly controlled research produces ambiguous results which research produces ambiguous results which are then interpreted according to the are then interpreted according to the prejudices of the reader. Anecdotes seem prejudices of the reader. Anecdotes seem to be more readily accepted when they to be more readily accepted when they point to adverse rather than positive effects point to adverse rather than positive effects (Hall (Hall et al et al, 1994 ). Yet the known adverse , 1994). Yet the known adverse effects of oral cannabinoids are rarely intol-effects of oral cannabinoids are rarely intolerable or life-threatening, in contrast to erable or life-threatening, in contrast to those associated with some standard thera-those associated with some standard therapies. A British Medical Association survey pies. A British Medical Association survey indicated that many UK doctors believe indicated that many UK doctors believe that cannabis should once again be avail-that cannabis should once again be available on prescription (Meek, 1994) . able on prescription (Meek, 1994) .
The way forward The way forward
A Select Committee of the House of Lords A Select Committee of the House of Lords recently examined the scientific information recently examined the scientific information concerning medical cannabis and took concerning medical cannabis and took verbal and written evidence from a wide verbal and written evidence from a wide range of witnesses. Their conclusion range of witnesses. Their conclusion (House of Lords, 1998) published in (House of Lords, 1998) published in November 1998, was that, although canna-November 1998, was that, although cannabis should remain a controlled drug, the bis should remain a controlled drug, the law should be changed to allow doctors to law should be changed to allow doctors to prescribe``an appropriate preparation of prescribe``an appropriate preparation of cannabis if they saw fit''. The government cannabis if they saw fit''. The government rejected this recommendation on the day rejected this recommendation on the day of publication. of publication.
Under the auspices of the Royal Under the auspices of the Royal Pharmaceutical Society, large-scale multi-Pharmaceutical Society, large-scale multicentre trials are under way to explore centre trials are under way to explore further the efficacy of cannabinoids in further the efficacy of cannabinoids in relieving spasticity and postoperative pain. relieving spasticity and postoperative pain. A pharmaceutical company has obtained a A pharmaceutical company has obtained a licence to cultivate medicinal cannabis on licence to cultivate medicinal cannabis on a large scale in the UK. By selecting a a large scale in the UK. By selecting a specific genotype then carefully controlling specific genotype then carefully controlling all other relevant variables such as soil con-all other relevant variables such as soil conditions, temperature and humidity, it is ditions, temperature and humidity, it is possible to obtain levels of purity in plant possible to obtain levels of purity in plant extracts equal or superior to those of`pure' extracts equal or superior to those of`pure' synthetic cannabinoids. Most of the 60 or synthetic cannabinoids. Most of the 60 or so naturally occurring cannabinoids are so naturally occurring cannabinoids are present in tiny amounts, and synthetic present in tiny amounts, and synthetic cannabinoids such as nabilone themselves cannabinoids such as nabilone themselves contain up to 5% impurities, some of contain up to 5% impurities, some of which are of unknown identity. Whether which are of unknown identity. Whether obtained by synthetic means or by plant obtained by synthetic means or by plant extraction, it is essential that cannabinoids extraction, it is essential that cannabinoids for prescription and research in the future for prescription and research in the future should demonstrate excellent purity, stability should demonstrate excellent purity, stability and bioavailability. and bioavailability.
The medicinal properties of cannabis The medicinal properties of cannabis are still mainly delineated by the anecdotal are still mainly delineated by the anecdotal reports of those who believe their symptoms reports of those who believe their symptoms are relieved by its use, and these accounts are relieved by its use, and these accounts are often dismissed as wishful thinking or are often dismissed as wishful thinking or even mischievous. Since the conventional even mischievous. Since the conventional treatments for many of these disorders are treatments for many of these disorders are both toxic and relatively both toxic and relatively ineffectual, a more ineffectual, a more constructive response would be to expose constructive response would be to expose such claims to careful scientific examination such claims to careful scientific examination and, in the meantime, search for a way to and, in the meantime, search for a way to avoid criminalising avoid criminalising those who seek only to those who seek only to assuage their own suffering. assuage their own suffering. 
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Existing anti-emetics Existing anti-emetics
Phenothiazzines Phenothiazzines and and butyrophenones butyrophenones can cause can cause sedation, movement disorders which may be sedation, movement disorders which may be irreversible, neuroleptic malignant syndrome, dry irreversible, neuroleptic malignant syndrome, dry mouth, blurred vision, urinary retention, hypo-mouth, blurred vision, urinary retention, hypotension, allergic reactions, jaundice, hypothermia, tension, allergic reactions, jaundice, hypothermia, hormonal disturbances, irreversible eye damage hormonal disturbances, irreversible eye damage and, rarely, life-threatening anaemias. and, rarely, life-threatening anaemias. Domperidone Domperidone has a more benign profile but is not recommended has a more benign profile but is not recommended for long-term use. for long-term use. Metoclopramide
Metoclopramide produces move-produces movement disorders (1% of patients), dizziness and ment disorders (1% of patients), dizziness and drowsiness. Selective 5-HT drowsiness. Selective 5-HT 3 3 antagonists ( antagonists (ondanse-ondansetron tron, , granisetron granisetron) are newer and more expensive. ) are newer and more expensive. Side-effects include constipation, headache, flushing, Side-effects include constipation, headache, flushing, liver enzyme changes, allergic reactions, visual liver enzyme changes, allergic reactions, visual disturbances, chest pain and dysrhythmias. disturbances, chest pain and dysrhythmias.
Existing neurological treatments Existing neurological treatments
Baclofen Baclofen alleviates spasticity, but may accentuate alleviates spasticity, but may accentuate muscle weakness. It produces dose-related nausea muscle weakness. It produces dose-related nausea and vomiting, drowsiness, vertigo, confusion, fatigue and vomiting, drowsiness, vertigo, confusion, fatigue and hypotonia. Less commonly, fits, psychiatric dis-and hypotonia. Less commonly, fits, psychiatric disorder and hypotension occur. Sudden withdrawal order and hypotension occur. Sudden withdrawal can cause hallucinations. can cause hallucinations. Diazepam
Diazepam is useful but can is useful but can worsen weakness or incoordination and cause worsen weakness or incoordination and cause drowsiness, ataxia, depression, disinhibition and drowsiness, ataxia, depression, disinhibition and dependence. dependence. Dantrolene
Dantrolene may cause weakness, hypo-may cause weakness, hypotonia, drowsiness, dizziness, vertigo and anxiety. tonia, drowsiness, dizziness, vertigo and anxiety. Rarely, it damages the liver, and is not recom-Rarely, it damages the liver, and is not recommended in those with co-existing heart or lung mended in those with co-existing heart or lung disease. disease. 
Existing glaucoma treatments Existing glaucoma treatments
Institute of Medicine
Dronabinol and prochlorperazine in combination are Dronabinol and prochlorperazine in combination are better than either agent alone for treatment of better than either agent alone for treatment of chemotherapy-induced nausea and vomiting. chemotherapy-induced nausea and vomiting. Merritt, J. C., Crawford, W. J., Alexander, P. C., Merritt, J. C., Crawford,W. J., Alexander, P. C., et al et al (1980) (1980) Effect of marihuana on intraocular and blood Effect of marihuana on intraocular and blood pressure in glaucoma. pressure in glaucoma. Ophthalmology Ophthalmology, , 87 87, 222^228. , 222^228. (1987) Delta-9-THC in the treatment Delta-9-THC in the treatment of spasticity associated with multiple sclerosis. of spasticity associated with multiple sclerosis. Advances Advances in Alcoholism and Substance Abuse in Alcoholism and Substance Abuse, , 7 7, 39^50. , 39^50.
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CLINICAL IMPLICATIONS CLINICAL IMPLICATIONS
& & Cannabis and its derivatives show promise of beneficial effects in a number of Cannabis and its derivatives show promise of beneficial effects in a number of medical conditions for which standard treatment is less than satisfactory, and further medical conditions for which standard treatment is less than satisfactory, and further controlled research is fully justified. controlled research is fully justified.
& & Cannabis is very safe in overdose, but often produces unwanted effects which are Cannabis is very safe in overdose, but often produces unwanted effects which are better tolerated by patients with some conditions (e.g. multiple sclerosis, chronic better tolerated by patients with some conditions (e.g. multiple sclerosis, chronic pain, AIDS, cancer) than others (e.g. glaucoma). pain, AIDS, cancer) than others (e.g. glaucoma). 
